$TCRT
Alaunos Therapeutics, Inc. Stock $tcrt

$tcrt Overview Financials Valuation SEC Filings Company Website

2024 Q1 Form 10-K Financial Statement

#000095017024038868 Filed on April 01, 2024

Income Statement

Concept	2024 Q1	2023 Q4	2023
Revenue	$1.000K	$1.000K	$5.000K
YoY Change		-90.91%	-99.83%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$1.617M	$2.428M	$12.22M
YoY Change	-48.96%	-16.99%	-7.02%
% of Gross Profit
Research & Development	$126.0K	$933.0K	$16.28M
YoY Change	-98.06%	-83.36%	-34.93%
% of Gross Profit
Depreciation & Amortization	$2.000K	$245.0K	$2.315M
YoY Change	-99.71%	-64.7%	-17.32%
% of Gross Profit
Operating Expenses	$1.743M	$3.361M	$28.50M
YoY Change	-81.98%	-60.61%	-25.06%
Operating Profit	-$1.742M		-$34.27M
YoY Change	-81.99%		-2.39%
Interest Expense	$0.00	$0.00	-$1.921M
YoY Change	-100.0%	-100.0%	-160.91%
% of Operating Profit
Other Income/Expense, Net	$60.00K	$106.0K	$1.048M
YoY Change	-115.96%	-57.6%	-139.92%
Pretax Income	-$1.682M	-$7.843M	-$35.14M
YoY Change	-83.26%	-14.37%	-6.86%
Income Tax
% Of Pretax Income
Net Earnings	-$1.682M	-$7.843M	-$35.14M
YoY Change	-83.26%	-14.37%	-6.86%
Net Earnings / Revenue	-168200.0%	-784300.0%	-702800.0%
Basic Earnings Per Share	-$0.11		-$2.20
Diluted Earnings Per Share	-$0.11	-$0.49	-$2.20
COMMON SHARES
Basic Shares Outstanding	16.01M	240.6M	16.00M
Diluted Shares Outstanding	16.01M		16.00M

Balance Sheet

Concept	2024 Q1	2023 Q4	2023
SHORT-TERM ASSETS
Cash & Short-Term Investments	$4.145M	$6.062M	$6.062M
YoY Change	-82.36%	-84.48%	-84.48%
Cash & Equivalents	$4.145M	$6.062M	$6.062M
Short-Term Investments
Other Short-Term Assets	$1.891M	$2.198M	$2.198M
YoY Change	-87.13%	-85.09%	-85.09%
Inventory
Prepaid Expenses
Receivables	$1.000K	$1.000K	$1.000K
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$6.037M	$8.261M	$8.261M
YoY Change	-84.19%	-84.64%	-84.64%
LONG-TERM ASSETS
Property, Plant & Equipment	$0.00	$2.000K	$2.000K
YoY Change	-100.0%	-99.98%	-99.98%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets		$0.00	$0.00
YoY Change		-100.0%	-100.0%
Total Long-Term Assets	$0.00	$2.000K	$2.000K
YoY Change	-100.0%	-99.98%	-99.98%
TOTAL ASSETS
Total Short-Term Assets	$6.037M	$8.261M	$8.261M
Total Long-Term Assets	$0.00	$2.000K	$2.000K
Total Assets	$6.037M	$8.263M	$8.263M
YoY Change	-87.59%	-87.28%	-87.28%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$597.0K	$616.0K	$616.0K
YoY Change	-56.74%	-55.65%	-55.65%
Accrued Expenses	$643.0K	$1.340M	$1.340M
YoY Change	-84.39%	-75.43%	-77.71%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due		$0.00	$0.00
YoY Change		-100.0%	-100.0%
Total Short-Term Liabilities	$1.240M	$1.956M	$1.956M
YoY Change	-92.73%	-91.91%	-91.91%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities		$0.00	$0.00
YoY Change		-100.0%	-100.0%
Total Long-Term Liabilities	$0.00	$0.00	$0.00
YoY Change	-100.0%	-100.0%	-100.0%
TOTAL LIABILITIES
Total Short-Term Liabilities	$1.240M	$1.956M	$1.956M
Total Long-Term Liabilities	$0.00	$0.00	$0.00
Total Liabilities	$1.240M	$1.956M	$1.956M
YoY Change	-93.52%	-92.59%	-92.59%
SHAREHOLDERS EQUITY
Retained Earnings	-$917.4M	-$915.8M
YoY Change	3.0%	4.0%
Common Stock	$922.2M	$922.1M
YoY Change	0.22%	0.31%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$4.797M	$6.307M	$6.307M
YoY Change
Total Liabilities & Shareholders Equity	$6.037M	$8.263M	$8.263M
YoY Change	-87.59%	-87.28%	-87.28%

Cashflow Statement

Concept	2024 Q1	2023 Q4	2023
OPERATING ACTIVITIES
Net Income	-$1.682M	-$7.843M	-$35.14M
YoY Change	-83.26%	-14.37%	-6.86%
Depreciation, Depletion And Amortization	$2.000K	$245.0K	$2.315M
YoY Change	-99.71%	-64.7%	-17.32%
Cash From Operating Activities	-$1.917M	-$7.382M	-$30.14M
YoY Change	-79.57%	3.53%	3.11%
INVESTING ACTIVITIES
Capital Expenditures	$0.00	-$3.000K	$197.0K
YoY Change	-100.0%	-102.59%	-8.8%
Acquisitions
YoY Change
Other Investing Activities	$0.00	$1.503M	$1.543M
YoY Change	-100.0%	6434.78%	6608.7%
Cash From Investing Activities	$0.00	$1.506M	$1.346M
YoY Change	-100.0%	-1719.35%	-797.41%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net			$92.00K
YoY Change			-100.63%
Debt Paid & Issued, Net	$0.00		$18.11M
YoY Change	-100.0%		117.27%
Cash From Financing Activities	0.000	2.000K	-18.14M
YoY Change	-100.0%	-99.98%	-384.88%
NET CHANGE
Cash From Operating Activities	-1.917M	-7.382M	-30.14M
Cash From Investing Activities	0.000	1.506M	1.346M
Cash From Financing Activities	0.000	2.000K	-18.14M
Net Change In Cash	-1.917M	-5.874M	-46.93M
YoY Change	-87.68%	-569.54%	103.55%
FREE CASH FLOW
Cash From Operating Activities	-$1.917M	-$7.382M	-$30.14M
Capital Expenditures	$0.00	-$3.000K	$197.0K
Free Cash Flow	-$1.917M	-$7.379M	-$30.34M
YoY Change	-79.7%	1.84%	3.03%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value
CY2023	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2023	dei	Entity Central Index Key EntityCentralIndexKey	0001107421
CY2023	dei	Amendment Flag AmendmentFlag	false
CY2023Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2022Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2023	dei	Document Type DocumentType	10-K
CY2023	dei	Document Annual Report DocumentAnnualReport	true
CY2023	dei	Document Period End Date DocumentPeriodEndDate	2023-12-31
CY2023	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2023	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
CY2023	dei	Document Transition Report DocumentTransitionReport	false
CY2023	dei	Entity File Number EntityFileNumber	001-33038
CY2023	dei	Entity Registrant Name EntityRegistrantName	Alaunos Therapeutics, Inc.
CY2023	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2023	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	84-1475642
CY2023	dei	Entity Address Address Line1 EntityAddressAddressLine1	2617 Bissonnet Street,
CY2023	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 225
CY2023	dei	Entity Address City Or Town EntityAddressCityOrTown	Houston
CY2023	dei	Entity Address State Or Province EntityAddressStateOrProvince	TX
CY2023	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	77005
CY2023	dei	City Area Code CityAreaCode	346
CY2023	dei	Local Phone Number LocalPhoneNumber	355-4099
CY2023	dei	Security12b Title Security12bTitle	Common Stock
CY2023	dei	Trading Symbol TradingSymbol	TCRT
CY2023	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2023	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2023	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2023	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2023	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2023	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2023	dei	Entity Small Business EntitySmallBusiness	true
CY2023	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2023	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	false
CY2023	dei	Document Fin Stmt Error Correction Flag DocumentFinStmtErrorCorrectionFlag	false
CY2023	dei	Entity Shell Company EntityShellCompany	false
CY2023Q2	dei	Entity Public Float EntityPublicFloat	94764946
CY2024Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	16012479
CY2023Q4	ecd	Rule10b51 Arr Adopted Flag Rule10b51ArrAdoptedFlag	false
CY2023Q4	ecd	Rule10b51 Arr Trmntd Flag Rule10b51ArrTrmntdFlag	false
CY2023Q4	ecd	Non Rule10b51 Arr Adopted Flag NonRule10b51ArrAdoptedFlag	false
CY2023Q4	ecd	Non Rule10b51 Arr Trmntd Flag NonRule10b51ArrTrmntdFlag	false
CY2023	dei	Auditor Name AuditorName	RSM US LLP
CY2023	dei	Auditor Location AuditorLocation	Boston, MA
CY2023	dei	Auditor Firm AuditorFirmId	49
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	6062000
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	39058000
CY2023Q4	us-gaap	Restricted Cash Current RestrictedCashCurrent	0
CY2022Q4	us-gaap	Restricted Cash Current RestrictedCashCurrent	13938000
CY2023Q4	us-gaap	Receivables Net Current ReceivablesNetCurrent	1000
CY2022Q4	us-gaap	Receivables Net Current ReceivablesNetCurrent	4000
CY2023Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	2198000
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	799000
CY2023Q4	us-gaap	Assets Current AssetsCurrent	8261000
CY2022	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	2922000
CY2023	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	16279000
CY2022	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	25018000
CY2023	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	12219000
CY2022Q4	us-gaap	Assets Current AssetsCurrent	53799000
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	2000
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	8460000
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	0
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	2136000
CY2023Q4	us-gaap	Deposits Assets Noncurrent DepositsAssetsNoncurrent	0
CY2022Q4	us-gaap	Deposits Assets Noncurrent DepositsAssetsNoncurrent	42000
CY2023Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	0
CY2022Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	500000
CY2023Q4	us-gaap	Assets Assets	8263000
CY2022Q4	us-gaap	Assets Assets	64937000
CY2023Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	616000
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	1389000
CY2023Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	0
CY2022Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	16765000
CY2023Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	1340000
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	5454000
CY2023Q4	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	0
CY2022Q4	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	558000
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	1956000
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	24166000
CY2023Q4	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent	0
CY2022Q4	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent	2188000
CY2023Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	0
CY2022Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	28000
CY2023Q4	us-gaap	Liabilities Liabilities	1956000
CY2022Q4	us-gaap	Liabilities Liabilities	26382000
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	34666667
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	16012522
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	16012522
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	28000000
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	16027384
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	16027384
CY2023Q4	us-gaap	Common Stock Value CommonStockValue	16000
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	16000
CY2023Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	922058000
CY2022Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	919166000
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-915767000
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-880627000
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	6307000
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	38555000
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	8263000
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	64937000
CY2023	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	5000
CY2023	us-gaap	Gain Loss On Termination Of Lease GainLossOnTerminationOfLease	298000
CY2022	us-gaap	Gain Loss On Termination Of Lease GainLossOnTerminationOfLease	133000
CY2022	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	13142000
CY2023	tcrt	Gain Loss On Operating Lease Modification And Termination GainLossOnOperatingLeaseModificationAndTermination	298000
CY2022	tcrt	Gain Loss On Operating Lease Modification And Termination GainLossOnOperatingLeaseModificationAndTermination	133000
CY2023	us-gaap	Restructuring Charges RestructuringCharges	1269000
CY2022	us-gaap	Restructuring Charges RestructuringCharges	0
CY2023	tcrt	Property And Equipment And Right Of Use Assets Impairment PropertyAndEquipmentAndRightOfUseAssetsImpairment	4803000
CY2022	tcrt	Property And Equipment And Right Of Use Assets Impairment PropertyAndEquipmentAndRightOfUseAssetsImpairment	0
CY2023	us-gaap	Operating Expenses OperatingExpenses	34272000
CY2022	us-gaap	Operating Expenses OperatingExpenses	38027000
CY2023	us-gaap	Operating Income Loss OperatingIncomeLoss	-34267000
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	-35105000
CY2023	us-gaap	Interest Expense InterestExpense	1921000
CY2022	us-gaap	Interest Expense InterestExpense	3154000
CY2023	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	1048000
CY2022	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	529000
CY2023	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-873000
CY2022	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-2625000
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-35140000
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-37730000
CY2023	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-2.2
CY2023	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-2.2
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-2.61
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-2.61
CY2023	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	15995323
CY2023	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	15995323
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	14475354
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	14475354
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	58057000
CY2022	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	3528000
CY2022	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	21000
CY2022	us-gaap	Stock Repurchased During Period Value StockRepurchasedDuringPeriodValue	45000
CY2022	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	14724000
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-37730000
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	38555000
CY2023	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	2800000
CY2023	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	92000
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-35140000
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	6307000
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-35140000
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-37730000
CY2023	us-gaap	Depreciation Depreciation	2315000
CY2022	us-gaap	Depreciation Depreciation	2759000
CY2023	us-gaap	Asset Impairment Charges AssetImpairmentCharges	4803000
CY2022	us-gaap	Asset Impairment Charges AssetImpairmentCharges	0
CY2023	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	1339000
CY2022	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	981000
CY2023	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	-7000
CY2022	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	-7000
CY2023	us-gaap	Employee Benefits And Share Based Compensation Noncash EmployeeBenefitsAndShareBasedCompensationNoncash	2800000
CY2022	us-gaap	Employee Benefits And Share Based Compensation Noncash EmployeeBenefitsAndShareBasedCompensationNoncash	3528000
CY2023	tcrt	Increase Decrease In Right Of Use Asset IncreaseDecreaseInRightOfUseAsset	-286000
CY2022	tcrt	Increase Decrease In Right Of Use Asset IncreaseDecreaseInRightOfUseAsset	-486000
CY2023	us-gaap	Increase Decrease In Receivables IncreaseDecreaseInReceivables	-3000
CY2022	us-gaap	Increase Decrease In Receivables IncreaseDecreaseInReceivables	-1107000
CY2023	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	1399000
CY2022	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-867000
CY2023	tcrt	Increase Decrease In Operating Deposits IncreaseDecreaseInOperatingDeposits	42000
CY2022	tcrt	Increase Decrease In Operating Deposits IncreaseDecreaseInOperatingDeposits	0
CY2023	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	-500000
CY2022	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	-131000
CY2023	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-773000
CY2022	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-25000
CY2023	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-3989000
CY2022	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-668000
CY2023	tcrt	Increase Decrease In Lease Liabilities IncreaseDecreaseInLeaseLiabilities	-610000
CY2022	tcrt	Increase Decrease In Lease Liabilities IncreaseDecreaseInLeaseLiabilities	-570000
CY2023	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	-28000
CY2022	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	28000
CY2023	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-30142000
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-29232000
CY2023	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	197000
CY2022	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	216000
CY2023	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	1543000
CY2022	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	23000
CY2023	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	1346000
CY2022	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-193000
CY2023	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	92000
CY2022	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	14724000
CY2023	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	0
CY2022	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	21000
CY2023	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	0
CY2022	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	45000
CY2023	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	18105000
CY2022	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	8333000
CY2023	us-gaap	Payments Of Debt Extinguishment Costs PaymentsOfDebtExtinguishmentCosts	125000
CY2022	us-gaap	Payments Of Debt Extinguishment Costs PaymentsOfDebtExtinguishmentCosts	0
CY2023	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-18138000
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	6367000
CY2023	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-46934000
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-23058000
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	52996000
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	76054000
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	6062000
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	52996000
CY2023	us-gaap	Interest Paid Net InterestPaidNet	2063000
CY2022	us-gaap	Interest Paid Net InterestPaidNet	2171000
CY2023	tcrt	Reduction In Right Of Use Assets For Modification And Termination ReductionInRightOfUseAssetsForModificationAndTermination	1839000
CY2022	tcrt	Reduction In Right Of Use Assets For Modification And Termination ReductionInRightOfUseAssetsForModificationAndTermination	1790000
CY2023	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	0
CY2022	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	91000
CY2023Q3	tcrt	Strategic Advisor Name StrategicAdvisorName	Cantor
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	6100000
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-915800000
CY2023	us-gaap	Use Of Estimates UseOfEstimates	<p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Use of Estimates</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Although the Company regularly assesses these estimates, actual results could differ from those estimates. Changes in estimates are recorded in the period in which they become known.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company’s most significant estimates and judgments used in the preparation of the financial statements are:</span></p><div style="margin-left:6.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.86108878960282%;display:inline-flex;justify-content:flex-start;">•</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Clinical trial expenses and other research and development expenses;</span></div></div><div style="margin-left:6.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.86108878960282%;display:inline-flex;justify-content:flex-start;">•</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Collaboration agreements;</span></div></div><div style="margin-left:6.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.86108878960282%;display:inline-flex;justify-content:flex-start;">•</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Fair value measurements of stock-based compensation; and</span></div></div><div style="margin-left:6.667%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.86108878960282%;display:inline-flex;justify-content:flex-start;">•</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Income taxes.</span></div></div>
CY2023	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Concentrations of Credit Risk</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Financial instruments which potentially subject the Company to concentrations of credit risk consist principally of cash and cash equivalents. The Company maintains cash accounts in commercial banks, which may, at times, exceed federally insured limits. The Company has not experienced any losses in such accounts. The Company believes it is not exposed to any significant credit risk on cash and cash equivalents.</span></p>
CY2022Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	169000
CY2023Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	1340000
CY2023Q3	us-gaap	Tangible Asset Impairment Charges TangibleAssetImpairmentCharges	4800000
CY2023	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	5000
CY2022	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	2900000
CY2023	us-gaap	Share Based Compensation ShareBasedCompensation	2800000
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	3528000
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	5.58
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	11.54
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	5454000
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.0351
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum	0.0401
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.0163
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum	0.0421
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum	0.8969
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum	1.1212
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum	0.7449
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum	0.8875
CY2024Q1	tcrt	Pre Stock Split Shares Authorized PreStockSplitSharesAuthorized	520000000
CY2024Q1	tcrt	Post Stock Split Shares Authorized PostStockSplitSharesAuthorized	34666667
CY2024Q1	us-gaap	Stockholders Equity Reverse Stock Split StockholdersEquityReverseStockSplit	The Charter Amendment became effective on January 31, 2024 at 5:00 p.m. Eastern Time, at which time every 15 shares of the Company’s issued and outstanding common stock automatically combined and converted into 1 share of common stock.
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-35140000
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-37730000
CY2023	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	15995323
CY2023	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	15995323
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	14475354
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	14475354
CY2023	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-2.2
CY2023	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-2.2
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-2.61
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-2.61
CY2023	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	1918297
CY2022	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	2284669
CY2023Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	0
CY2022Q4	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	16765000
CY2022Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	16765000
CY2022Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	0
CY2021Q3	us-gaap	Debt Instrument Basis Spread On Variable Rate1 DebtInstrumentBasisSpreadOnVariableRate1	0.045
CY2023	us-gaap	Interest Expense Debt InterestExpenseDebt	1900000
CY2022	us-gaap	Interest Expense Debt InterestExpenseDebt	3200000
CY2023Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	15000
CY2022Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	18267000
CY2023Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	13000
CY2022Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	9807000
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	2000
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	8460000
CY2023	us-gaap	Depreciation Depreciation	2300000
CY2022	us-gaap	Depreciation Depreciation	2800000
CY2023Q4	tcrt	Accrued Clinical Expenses Current AccruedClinicalExpensesCurrent	568000
CY2022Q4	tcrt	Accrued Clinical Expenses Current AccruedClinicalExpensesCurrent	2200000
CY2023Q4	us-gaap	Accrued Bonuses Current AccruedBonusesCurrent	43000
CY2022Q4	us-gaap	Accrued Bonuses Current AccruedBonusesCurrent	1160000
CY2023Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	717000
CY2022Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	534000
CY2023Q4	tcrt	Accrued Preclinical Services Current AccruedPreclinicalServicesCurrent	0
CY2022Q4	tcrt	Accrued Preclinical Services Current AccruedPreclinicalServicesCurrent	198000
CY2023Q4	tcrt	Accrued Manufacturing Costs Current AccruedManufacturingCostsCurrent	12000
CY2022Q4	tcrt	Accrued Manufacturing Costs Current AccruedManufacturingCostsCurrent	1177000
CY2023Q4	tcrt	Accrued Consulting Fees Current AccruedConsultingFeesCurrent	0
CY2022Q4	tcrt	Accrued Consulting Fees Current AccruedConsultingFeesCurrent	16000
CY2023Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	0
CY2022	tcrt	Gain Loss On Modification Of Lease GainLossOnModificationOfLease	100000
CY2022Q2	tcrt	Sublease Area SubleaseArea	4772
CY2023	tcrt	Lease Termination Date LeaseTerminationDate	2023-04-19
CY2023Q2	us-gaap	Lessee Operating Lease Option To Extend LesseeOperatingLeaseOptionToExtend	a term expiring on June 30, 2025 with an option to extend through July 31, 2026
CY2023Q2	tcrt	Sublease Term Commenced End Date Amendment SubleaseTermCommencedEndDateAmendment	2026-07-31
CY2023	tcrt	Termination Costs TerminationCosts	200000
CY2023Q4	tcrt	Operating Lease Area OperatingLeaseArea	14037
CY2023Q4	us-gaap	Operating Lease Payments OperatingLeasePayments	100000
CY2023	us-gaap	Operating Lease Cost OperatingLeaseCost	428000
CY2022	us-gaap	Operating Lease Cost OperatingLeaseCost	756000
CY2023	us-gaap	Lease Cost LeaseCost	428000
CY2022	us-gaap	Lease Cost LeaseCost	756000
CY2022Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P4Y1M17D
CY2023Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0
CY2022Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.0826
CY2023	us-gaap	Operating Lease Payments OperatingLeasePayments	400000
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	0
CY2023	us-gaap	Short Term Lease Cost ShortTermLeaseCost	0
CY2018Q4	tcrt	Maximum Royalty Amount MaximumRoyaltyAmount	100000000
CY2023	us-gaap	Royalty Expense RoyaltyExpense	0
CY2022	us-gaap	Royalty Expense RoyaltyExpense	0
CY2023Q1	us-gaap	Loss Contingency Name Of Plaintiff LossContingencyNameOfPlaintiff	KBI Biopharma
CY2023Q1	us-gaap	Loss Contingency Damages Sought Value LossContingencyDamagesSoughtValue	3200000
CY2023Q4	us-gaap	Litigation Settlement Expense LitigationSettlementExpense	1000000
CY2019Q3	us-gaap	Proceeds From Issuance Of Private Placement ProceedsFromIssuanceOfPrivatePlacement	52500000
CY2023	us-gaap	Severance Costs1 SeveranceCosts1	1300000
CY2023Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	148009000
CY2022Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	171070000
CY2023Q4	tcrt	Deferred Tax Assets Start Up And Pre Clinical Studies DeferredTaxAssetsStartUpAndPreClinicalStudies	13754000
CY2022Q4	tcrt	Deferred Tax Assets Start Up And Pre Clinical Studies DeferredTaxAssetsStartUpAndPreClinicalStudies	17204000
CY2023Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	39838000
CY2022Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	40116000
CY2023Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits	681000
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits	698000
CY2023Q4	tcrt	Deferred Tax Assets Capitalized Acquisition Costs DeferredTaxAssetsCapitalizedAcquisitionCosts	1570000
CY2022Q4	tcrt	Deferred Tax Assets Capitalized Acquisition Costs DeferredTaxAssetsCapitalizedAcquisitionCosts	2180000
CY2023Q4	tcrt	Deferred Tax Assets Lease Liability DeferredTaxAssetsLeaseLiability	0
CY2022Q4	tcrt	Deferred Tax Assets Lease Liability DeferredTaxAssetsLeaseLiability	618000
CY2023Q4	tcrt	Deferred Tax Assets Depreciation DeferredTaxAssetsDepreciation	1000
CY2022Q4	tcrt	Deferred Tax Assets Depreciation DeferredTaxAssetsDepreciation	239000
CY2023Q4	tcrt	Deferred Tax Assets Research Expenses Capitalized DeferredTaxAssetsResearchExpensesCapitalized	7176000
CY2022Q4	tcrt	Deferred Tax Assets Research Expenses Capitalized DeferredTaxAssetsResearchExpensesCapitalized	5156000
CY2023Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	2000
CY2022Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	27000
CY2023Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	211031000
CY2022Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	237308000
CY2023Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	211031000
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	236827000
CY2023Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	0
CY2022Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	481000
CY2023Q4	tcrt	Deferred Tax Liability Right Of Use Asset DeferredTaxLiabilityRightOfUseAsset	0
CY2022Q4	tcrt	Deferred Tax Liability Right Of Use Asset DeferredTaxLiabilityRightOfUseAsset	481000
CY2023Q4	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	0
CY2022Q4	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	481000
CY2023Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	0
CY2022Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	0
CY2023Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards Not Subject To Expiration DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration	363200000
CY2023Q4	us-gaap	Tax Credit Carryforward Amount TaxCreditCarryforwardAmount	0
CY2023	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	-25800000
CY2023	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21
CY2022	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21
CY2023	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	-0.92
CY2022	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.03
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Research And Development EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment	0.02
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Research And Development EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment	0.02
CY2023	tcrt	Effective Income Tax Rate Reconciliation Nondeductible Expense Research And Development True Up EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopmentTrueUp	-0.01
CY2022	tcrt	Effective Income Tax Rate Reconciliation Nondeductible Expense Research And Development True Up EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopmentTrueUp	-0.02
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost	0
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost	-0.01
CY2023	tcrt	Effective Income Tax Rate Reconciliation Nondeductible Expense Federal Rate Change EffectiveIncomeTaxRateReconciliationNondeductibleExpenseFederalRateChange	-0.03
CY2022	tcrt	Effective Income Tax Rate Reconciliation Nondeductible Expense Federal Rate Change EffectiveIncomeTaxRateReconciliationNondeductibleExpenseFederalRateChange	-0.05
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	0.73
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.18
CY2023	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0
CY2022	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0
CY2023	us-gaap	Unrecognized Tax Benefits Period Increase Decrease UnrecognizedTaxBenefitsPeriodIncreaseDecrease	0
CY2022	us-gaap	Unrecognized Tax Benefits Period Increase Decrease UnrecognizedTaxBenefitsPeriodIncreaseDecrease	0
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant	1302411
CY2023	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	0
CY2022	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	21000
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	26000
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	711058
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	43.05
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod	313167
CY2022	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	16.14
CY2022	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	1750
CY2022	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	12
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	328566
CY2022	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	50.1
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	693909
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	27.6
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod	259122
CY2023	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	7.35
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	487133
CY2023	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	17.7
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	465898
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	26.85
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P7Y9M21D
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	0
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	415376
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	28.8
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P7Y7M20D
CY2023Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	0
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant	1302411
CY2023	us-gaap	Defined Benefit Plan Contributions By Employer DefinedBenefitPlanContributionsByEmployer	200000
CY2022	us-gaap	Defined Benefit Plan Contributions By Employer DefinedBenefitPlanContributionsByEmployer	500000
CY2024Q1	tcrt	Advance Notice Period For Termination Agreement AdvanceNoticePeriodForTerminationAgreement	P30D

Files In Submission

Name	View Source	Status
0000950170-24-038868-index-headers.html	Edgar Link	pending
0000950170-24-038868-index.html	Edgar Link	pending
0000950170-24-038868.txt	Edgar Link	pending
0000950170-24-038868-xbrl.zip	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
img160836378_0.jpg	Edgar Link	pending
img160836378_1.jpg	Edgar Link	pending
img160836378_2.jpg	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
tcrt-20231231.htm	Edgar Link	pending
tcrt-20231231.xsd	Edgar Link	pending
tcrt-ex10_59.htm	Edgar Link	pending
tcrt-ex10_60.htm	Edgar Link	pending
tcrt-ex10_61.htm	Edgar Link	pending
tcrt-ex10_62.htm	Edgar Link	pending
tcrt-ex23_1.htm	Edgar Link	pending
tcrt-ex31_1.htm	Edgar Link	pending
tcrt-ex32_1.htm	Edgar Link	pending
tcrt-ex97_1.htm	Edgar Link	pending
tcrt-20231231_htm.xml	Edgar Link	completed

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$TCRT
Alaunos Therapeutics, Inc. Stock $tcrt

2024 Q1 Form 10-K Financial Statement

#000095017024038868 Filed on April 01, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$TCRT Alaunos Therapeutics, Inc. Stock $tcrt

2024 Q1 Form 10-K Financial Statement

#000095017024038868 Filed on April 01, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$TCRT
Alaunos Therapeutics, Inc. Stock $tcrt